In 2016, AAA officially opened its first production and distribution site in Milburn, New Jersey. office in New York City in 2014, and listed on the NASDAQ in 2015. In line with AAA’s growth strategy, the company has built a substantial beachhead in the United States. The team’s research produced a patent, which had applications in nuclear medicine, and Buono saw an opportunity to create a company to commercialize this patent and further develop the technology for theragnostic applications. ![]() Prior to founding AAA, Stefano Buono was a physicist at The European Organization for Nuclear Research (CERN) in Switzerland, working with Physics Nobel Laureate Carlo Rubbia. AAA is also developing a pipeline of theragnostic pairings for oncology indications. AAA employs over 500 employees in 13 countries (Belgium, Canada, France, Germany, Israel, Italy, the Netherlands, Poland, Portugal, Spain, Switzerland, the UK and the U.S.) and currently markets nine radiopharmaceuticals (8 in Europe and 1 in the U.S.) for diagnosis in oncology, cardiology and neurology. that manufacture both diagnostic and therapeutic MNM products. Today, AAA has over 21 production and research & development facilities in Europe and the U.S. AAA, headquartered in Saint-Genis-Pouilly, France was founded in 2002 by Stefano Buono. AAA is merging therapeutic and diagnostic technologies to advance the early detection, treatment and monitoring of diseases. AAA is a global leader in the development of predictive, preventive and personalized tools that may transform healthcare for patients and physicians. We celebrate you! Admera Health is one such company.Īdvanced Accelerator Applications (AAA) is a radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicine, or MNM, diagnostic and therapeutic products. The Swiss big pharma company has been steadily bulking up in cancer via bolt-on acquisitions, for example by buying up GlaxoSmithKline’s oncology assets in 2015 in a $16bn deal, acquiring US biopharma Admune Therapeutics and announcing a string of licensing deals for cancer candidates, mainly in immuno-oncology.So many of our Members are making a dramatic impact on our State’s innovation ecosystem. Latterly Sandostatin has played second fiddle to Afinitor, which is rolling out in multiple NET tumour types including gastrointestinal and lung NET last year and brought in $1.1bn in the same period. The popularity of a long-acting version means it It’s still a big earner for Novartis however, with sales of around $1.2bn in the first nine months of this year, down just 4%. ![]() Novartis has no heritage in this type of medicine but already markets two drugs for NET – Sandostatin (octreotide) and Afinitor/Votubia (everolimus) – so the acquisition makes sense from a franchise perspective, particularly as Sandostatin has now lost patent protection for the immediate-release formulation. AAA was spun out 15 years ago from Cern, the European nuclear research organisation. With the acquisition, Novartis is aiming to add AAA’s Lutathera (Lutetium Lu177 dotatate) for treating gastroenteropancreatic neuroendocrine tumours (NET) – approved in the EU and heading for an FDA decision towards the end of January – plus two commercial NET imaging agents (NetSpot and Somakit) already generating revenues.Īdded to that, the acquisition adds a pipeline of early-stage radionuclide candidates for other types of cancer, including several solid tumours including prostate cancer. The tender offer will expire at midnight on January 19 unless extended, said Novartis. Novartis offer to buy the company was made in October and – after negotiations with company’s works council – AAA’s board has now given its blessing to the $41 per share takeover, which values the French company at $3.9bn. Novartis has started its cash tender offer for French firm Advanced Accelerator Applications, which specialises in radiopharmaceuticals to treat cancer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |